TrialMedicine2018

Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.

Nagalingeswaran Kumarasamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.